Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using peptide nucleic acids as gene-expression modifiers to reduce beta-amyloid levels.

Beth M McMahon1, Jennifer Stewart, Abdul Fauq

  • 1Departments of Neuroscience and Pharmacology, Mayo Clinic, Jacksonville, FL 32224, USA.

Journal of Molecular Neuroscience : MN
|September 6, 2002
PubMed
Summary

Peptide nucleic acids (PNAs) show promise in reducing amyloid beta (A beta) levels, a key factor in Alzheimer's disease. This approach targets amyloid precursor protein (APP) to potentially slow disease onset.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MAOI Antidepressants: A History Being Rewritten.

The Journal of clinical psychiatry·2025
Same author

Risk-Based Quality Management: A Case for Centralized Monitoring.

Therapeutic innovation & regulatory science·2024
Same author

X-chromosome-wide association study for Alzheimer's disease.

Molecular psychiatry·2024
Same author

Competency-Based Medical Education at Scale: A Road Map for Transforming National Systems of Postgraduate Medical Education.

Perspectives on medical education·2024
Same author

Correction: Flow Cytometry Method Validation Protocols.

Current protocols·2024
Same author

Primary small intestinal lymphangiosarcoma in a dog presenting with a segmental partial mesenteric volvulus.

Journal of comparative pathology·2023

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Amyloid beta (A beta) peptide deposition is a critical early event in Alzheimer's disease (AD).
  • Elevated A beta, particularly A beta(1-42), is implicated in AD pathogenesis, causing aggregation and neuronal death.
  • Reducing A beta levels is a therapeutic strategy to slow or prevent AD onset.

Purpose of the Study:

  • To investigate the efficacy of peptide nucleic acids (PNAs) in reducing A beta peptide levels in the brain.
  • To target amyloid precursor protein (APP) using PNA-based antisense or antigene strategies.
  • To evaluate PNA effectiveness in a mouse model for Alzheimer's disease research.

Main Methods:

  • Systemic administration of PNAs designed to target APP mRNA (antisense) or DNA (antigene).

Related Experiment Videos

  • Initial studies conducted in rats, followed by experiments in mice to prepare for transgenic AD models.
  • Quantification of A beta(1-40) and A beta(1-42) levels in mouse brain tissue.

    • Main Results:

    • A PNA sequence significantly reduced A beta(1-41) levels in rat brains.
    • Despite technical challenges in mice, one PNA sequence lowered mouse brain A beta(1-40) by 37% and A beta(1-42) by 47%.

    Conclusions:

    • PNAs represent a viable strategy for targeting APP to reduce pathogenic A beta species.
    • PNA-based approaches demonstrate potential for Alzheimer's disease therapeutic development.
    • Further research with PNAs in AD models is warranted to explore their full therapeutic potential.